Generate Biomedicines Valuation Multiples

Generate Biomedicines Overview

About Generate Biomedicines

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Founded

2018

HQ

Employees

132

Website

generatebiomedicines.com

Sectors

BiopharmaceuticalsLife Sciences ToolsBioTech

Financials (LTM)

Revenue: $30M

EBITDA: ($233M)

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Generate Biomedicines Financials

Generate Biomedicines reported last 12-month revenue of $30M and negative EBITDA of ($233M).

In the same LTM period, Generate Biomedicines generated $30M in gross profit, ($233M) in EBITDA losses, and had net loss of ($253M).

Generate Biomedicines P&L

In the most recent fiscal year, Generate Biomedicines reported revenue of $32M and EBITDA of ($208M).

Generate Biomedicines expects next 12-month revenue of XXX and NTM EBITDA of XXX

Generate Biomedicines Stock Performance

Generate Biomedicines has current market cap of $2B, and enterprise value of $1B.

Generate Biomedicines' stock price is $12.80.

Generate Biomedicines Valuation Multiples

Generate Biomedicines trades at 49.2x EV/Revenue multiple, and (6.3x) EV/EBITDA.

Generate Biomedicines Financial Valuation Multiples

As of April 14, 2026, Generate Biomedicines has market cap of $2B and EV of $1B.

Equity research analysts estimate Generate Biomedicines' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Generate Biomedicines has a P/E ratio of (6.5x).

Generate Biomedicines Margins & Growth Rates

Generate Biomedicines' revenue in the last 12 month declined by (17%).

Generate Biomedicines' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $2.0M for the same period.

Generate Biomedicines' rule of 40 is (1050%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Generate Biomedicines' rule of X is (1081%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Generate Biomedicines Public Comps

See public comps and valuation multiples for other Biopharmaceuticals and Life Sciences Tools comps.

Generate Biomedicines M&A Activity

Generate Biomedicines acquired XXX companies to date.

Last acquisition by Generate Biomedicines was on XXXXXXXX, XXXXX. Generate Biomedicines acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Generate Biomedicines Investment Activity

Generate Biomedicines invested in XXX companies to date.

Generate Biomedicines made its latest investment on XXXXXXXX, XXXXX. Generate Biomedicines invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).